A 31-year-old male Jehovah's Witness was diagnosed with non-Hodgkin's lymphoma (intermediate grade, stage 1KB). After treatment with VACOP-B (etoposide , adriamycin, cyclophosphamide, vincristine, prednisone and bleomycin) he achieved complete remission. Seven months later the patient relapsed and was treated with the DICE regimen (dexamethasone, ifosphamide, cisplatin and etoposide), achieving a partial remission.
Discussion
The following results were obtained from a survey held during the symposium. Delegates were invited to express their views by choosing from a multiple-choice list High-dose chemotherapy is associated with significant anaemia. However, opinions on the haemoglobin level at which it would be appropriate to offer high-dose chemotherapy were diverse. Just over one-third (35.8%) of the delegates would have considered high-dose chemotherapy at a haemoglobin level of 10 g/dl, 37.3% would have preferred a level of 12 g/dl before initiating therapy, 12.4% would have preferred a level of 14 g/dl and 14.5% of the delegates would not have offered highdose chemotherapy in this case study.
When asked to predict the patient's response to epoetin alfa given for two weeks before high-dose chemotherapy, the majority of delegates felt that there would be a rise to between 8.1 and 10 g/dl in haemoglobin level. Few delegates predicted that the haemoglobin would rise above 10 g/dl and most were surprised by the actual increase from 8.2 to 11.7 g/dl (Figure 1) .
When asked for their views on the use of epoetin alfa before bone marrow transplant, almost half (45.7%) of the delegates considered that avoiding the need for red blood cell transfusions was the main justification for the use of epoetin alfa in this setting. Over one-third (38.17%) of the audience considered that the possible synergistic effect of epoetin alfa with G-CSF on progenitor cell mobilisation was the most pertinent rationale. Delegates' prediction of change in haemoglobin levels when epoetin alfa was given for two weeks prior to high-dose chemotherapy. 
